Enable Injections said today that it inked a partnership with Sanofi for its enFuse drug delivery platform.
Cincinnati-based Enable Injections developed the enFuse device to enable patient-administered subcutaneous delivery of high-volume therapeutics outside of the hospital. The on-body drug delivery platform has a self-contained drug transfer system that is compatible with standard syringes and vial container formats.
The partnership with Sanofi will help Enable Injections to develop long-term manufacturing and supply arrangements using multiple molecule development programs provided by Sanofi. Sanofi currently has more than 70 projects under development and focuses on drug delivery solutions.
“Enable is delighted to partner with Sanofi in its mission to deliver patient-focused solutions,” president & CEO Michael Hooven said in a press release. “Enable Injections has engineered the enFuse with the patient experience in mind, with the aim of increasing adherence and achieving the outcomes necessary for our partners’ commercial success.”
EnFuse is designed for controlled subcutaneous administration of large volumes that range from 5ml to 50ml. The company says the device can give patients and caregivers a different delivery method for subcutaneous administration of parenteral therapies outside of the doctor’s office.
Enable Injections inked development deals with Apellis Pharmaceuticals and UCB for the enFuse device in November last year. It also closed a $50 million Series B round led by Sanofi in October 2018
